Dr Sherry Wu
Dr

Sherry Wu

Email: 
Phone: 
+61 7 336 52785

Availability

Dr Sherry Wu is:
Available for supervision

Qualifications

  • Bachelor (Honours), The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Search Professor Sherry Wu’s works on UQ eSpace

65 works between 2009 and 2025
All (65) Journal Article (59) Book Chapter (2) Conference Publication (4)

21 - 40 of 65 works

2019

Journal Article

Predicting novel therapies and targets: regulation of notch3 by the Bromodomain protein BRD4

Villar-Prados, Alejandro, Wu, Sherry Y., Court, Karem A., Ma, Shaolin, LaFargue, Christopher, Chowdhury, Mamur A., Engelhardt, Margaret I., Ivan, Cristina, Ram, Prahlad T., Wang, Ying, Baggerly, Keith, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Ming-Yang, Shyh, Maloney, David J., Yoshioka, Makoto, Strovel, Jeffrey W., Roszik, Jason and Sood, Anil K. (2019). Predicting novel therapies and targets: regulation of notch3 by the Bromodomain protein BRD4. Molecular Cancer Therapeutics, 18 (2), 421-436. doi: 10.1158/1535-7163.MCT-18-0365

Predicting novel therapies and targets: regulation of notch3 by the Bromodomain protein BRD4

2018

Journal Article

Advances and challenges in nanomedicine

Hua, Susan and Wu, Sherry Y. (2018). Advances and challenges in nanomedicine. Frontiers in Pharmacology, 9 (Nov) 1397, 1397. doi: 10.3389/fphar.2018.01397

Advances and challenges in nanomedicine

2018

Journal Article

The advances and challenges in utilizing exosomes for delivering cancer therapeutics

Yang, Mengliu and Wu, Sherry Y. (2018). The advances and challenges in utilizing exosomes for delivering cancer therapeutics. Frontiers in Pharmacology, 9 (JUL) 735, 735. doi: 10.3389/fphar.2018.00735

The advances and challenges in utilizing exosomes for delivering cancer therapeutics

2017

Journal Article

Immune cell profiling in cancer: molecular approaches to cell-specific identification

Lyons, Yasmin A., Wu, Sherry Y., Overwijk, Willem W., Baggerly, Keith A. and Sood, Anil K. (2017). Immune cell profiling in cancer: molecular approaches to cell-specific identification. Npj Precision Oncology, 1 (26) 26. doi: 10.1038/s41698-017-0031-0

Immune cell profiling in cancer: molecular approaches to cell-specific identification

2017

Journal Article

PRKCI promotes immune suppression in ovarian cancer

Sarkar, Sharmistha, Bristow, Christopher A., Dey, Prasenjit, Rai, Kunal, Perets, Ruth, Ramirez-Cardenas, Alejandra, Malasi, Shruti, Huang-Hobbs, Emmet, Haemmerle, Monika, Wu, Sherry Y., McGuire, Michael, Protopopov, Alexei, Jiang, Shan, Liu, Joyce F., Hirsch, Michelle S., Chang, Qing, Lazar, Alexander J., Sood, Anil K., Drapkin, Ronny, DePinho, Ronald, Draetta, Giulio and Chin, Lynda (2017). PRKCI promotes immune suppression in ovarian cancer. Genes and Development, 31 (11), 1109-1121. doi: 10.1101/gad.296640.117

PRKCI promotes immune suppression in ovarian cancer

2017

Journal Article

Preclinical mammalian safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)

Wagner, Michael J., Mitra, Rahul, McArthur, Mark J., Baze, Wallace, Barnhart, Kirstin, Wu, Sherry Y., Rodriguez-Aguayo, Cristian, Zhang, Xinna, Coleman, Robert L., Lopez-Berestein, Gabriel and Sood, Anil K. (2017). Preclinical mammalian safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Molecular Cancer Therapeutics, 16 (6), 1114-1123. doi: 10.1158/1535-7163.MCT-16-0541

Preclinical mammalian safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)

2017

Journal Article

HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer

Court, Karem A., Hatakeyama, Hiroto, Wu, Sherry Y., Lingegowda, Mangala S., Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Ju-Seog, Lee, Rinaldi, Carlos, Juan, Eduardo J., Sood, Anil K. and Torres-Lugo, Madeline (2017). HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Molecular Cancer Therapeutics, 16 (5), 966-976. doi: 10.1158/1535-7163.MCT-16-0519

HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer

2016

Journal Article

Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers

Hatakeyama, Hiroto, Wu, Sherry Y., Lyons, Yasmin A., Pradeep, Sunila, Wang, Wanqin, Huang, Qian, Court, Karem A., Liu, Tao, Nie, Song, Rodriguez-Aguayo, Cristian, Shen, Fangrong, Huang, Yan, Hisamatsu, Takeshi, Mitamura, Takashi, Jennings, Nicholas, Shim, Jeajun, Dorniak, Piotr L., Mangala, Lingegowda S., Petrillo, Marco, Petyuk, Vladislav A., Schepmoes, Athena A., Shukla, Anil K., Torres-Lugo, Madeline, Lee, Ju-Seog, Rodland, Karin D., Fagotti, Anna, Lopez-Berestein, Gabriel, Li, Chun and Sood, Anil K. (2016). Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers. Cell Reports, 17 (6), 1621-1631. doi: 10.1016/j.celrep.2016.10.020

Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers

2016

Journal Article

BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer

Yokoyama, Yuhki, Zhu, Hengrui, Lee, Jeong Heon, Kossenkov, Andrew V., Wu, Sherry Y., Wickramasinghe, Jayamanna M., Yin, Xiangfan, Palozola, Katherine C., Gardini, Alessandro, Showe, Louise C., Zaret, Kenneth S., Liu, Qin, Speicher, David, Conejo-Garcia, Jose R., Bradner, James E., Zhang, Zhiguo, Sood, Anil K., Ordog, Tamas, Bitler, Benjamin G. and Zhang, Rugang (2016). BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Research, 76 (21), 6320-6330. doi: 10.1158/0008-5472.CAN-16-0854

BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer

2016

Journal Article

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression

Rupaimoole, R., Ivan, C., Yang, D., Gharpure, K. M., Wu, S. Y., Pecot, C. V., Previs, R. A., Nagaraja, A. S., Armaiz-Pena, G. N., McGuire, M., Pradeep, S., Mangala, L. S., Rodriguez-Aguayo, C., Huang, L., Bar-Eli, M., Zhang, W., Lopez-Berestein, G., Calin, G. A. and Sood, A. K. (2016). Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene, 35 (33), 4312-4320. doi: 10.1038/onc.2015.492

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression

2016

Journal Article

Role of increased n-acetylaspartate Levels in cancer

Zand, Behrouz, Previs, Rebecca A., Zacharias, Niki M., Rupaimoole, Rajesha, Mitamura, Takashi, Nagaraja, Archana Sidalaghatta, Guindani, Michele, Dalton, Heather J., Yang, Lifeng, Baddour, Joelle, Achreja, Abhinav, Hu, Wei, Pecot, Chad V., Ivan, Cristina, Wu, Sherry Y., McCullough, Christopher R., Gharpure, Kshipra M., Shoshan, Einav, Pradeep, Sunila, Mangala, Lingegowda S., Rodriguez-Aguayo, Cristian, Wang, Ying, Nick, Alpa M., Davies, Michael A., Armaiz-Pena, Guillermo, Liu, Jinsong, Lutgendorf, Susan K., Baggerly, Keith A., Bar Eli, Menashe ... Sood, Anil K. (2016). Role of increased n-acetylaspartate Levels in cancer. JNCI-Journal of the National Cancer Institute, 108 (6), djv426. doi: 10.1093/jnci/djv426

Role of increased n-acetylaspartate Levels in cancer

2016

Journal Article

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal

Haemmerle, Monika, Bottsford-Miller, Justin, Pradeep, Sunila, Taylor, Morgan L., Choi, Hyun-Jin, Hansen, Jean M., Dalton, Heather J., Stone, Rebecca L., Cho, Min Soon, Nick, Alpa M., Nagaraja, Archana S., Gutschner, Tony, Gharpure, Kshipra M., Mangala, Lingegowda S., Rupaimoole, Rajesha, Han, Hee Dong, Zand, Behrouz, Armaiz-Pena, Guillermo N., Wu, Sherry Y., Pecot, Chad V., Burns, Alan R., Lopez-Berestein, Gabriel, Afshar-Kharghan, Vahid and Sood, Anil K. (2016). FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. Journal of Clinical Investigation, 126 (5), 1885-1896. doi: 10.1172/JCI85086

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal

2016

Journal Article

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer

Wu, Sherry Y., Rupaimoole, Rajesha, Shen, Fangrong, Pradeep, Sunila, Pecot, Chad V., Ivan, Cristina, Nagaraja, Archana S., Gharpure, Kshipra M., Pham, Elizabeth, Hatakeyama, Hiroto, McGuire, Michael H., Haemmerle, Monika, Vidal-Anaya, Viviana, Olsen, Courtney, Rodriguez-Aguayo, Cristian, Filant, Justyna, Ehsanipour, Ehsan A., Herbrich, Shelley M., Maiti, Sourindra N., Huang, Li, Kim, Ji Hoon, Zhang, Xinna, Han, Hee-Dong, Armaiz-Pena, Guillermo N., Seviour, Elena G., Tucker, Sue, Zhang, Min, Yang, Da, Cooper, Laurence J. N. ... Sood, Anil K. (2016). A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications, 7 (1) 11169. doi: 10.1038/ncomms11169

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer

2016

Book Chapter

Assessment of in Vivo siRNA delivery in cancer mouse models

Hatakeyama, Hiroto, Wu, Sherry Y., Mangala, Lingegowda S., Lopez-Berestein, Gabriel and Sood, Anil K. (2016). Assessment of in Vivo siRNA delivery in cancer mouse models. Long non-coding RNAs: methods and protocols. (pp. 189-197) edited by Yi Feng and Lin Zhang. Totowa, NJ USA: Humana Press. doi: 10.1007/978-1-4939-3378-5_15

Assessment of in Vivo siRNA delivery in cancer mouse models

2015

Journal Article

Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis

Rupaimoole, Rajesha, Lee, Jaehyuk, Haemmerle, Monika, Ling, Hui, Previs, Rebecca A., Pradeep, Sunila, Wu, Sherry Y., Ivan, Cristina, Ferracin, Manuela, Dennison, Jennifer B., Millward, Niki M. Zacharias, Nagaraja, Archana S., Gharpure, Kshipra M., McGuire, Michael, Sam, Nidhin, Armaiz-Pena, Guillermo N., Sadaoui, Nouara C., Rodriguez-Aguayo, Cristian, Calin, George A., Drapkin, Ronny I., Kovacs, Jeffery, Mills, Gordon B., Zhang, Wei, Lopez-Berestein, Gabriel, Bhattacharya, Pratip K. and Sood, Anil K. (2015). Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis. Cell Reports, 13 (11), 2395-2402. doi: 10.1016/j.celrep.2015.11.047

Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis

2015

Journal Article

Advances and challenges of liposome assisted drug delivery

Sercombe, Lisa, Veerati, Tejaswi, Moheimani, Fatemeh, Wu, Sherry Y., Sood, Anil K. and Hua, Susan (2015). Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6. doi: 10.3389/fphar.2015.00286

Advances and challenges of liposome assisted drug delivery

2015

Journal Article

Erythropoietin stimulates tumor growth via EphB4

Pradeep, Sunila, Huang, Jie, Mora, Edna M., Nick, Alpa M., Cho, Min Soon, Wu, Sherry Y., Noh, Kyunghee, Pecot, Chad V., Rupaimoole, Rajesha, Stein, Martin A., Brock, Stephan, Wen, Yunfei, Xiong, Chiyi, Gharpure, Kshipra, Hansen, Jean M., Nagaraja, Archana S., Previs, Rebecca A., Vivas-Mejia, Pablo, Han, Hee Dong, Hu, Wei, Mangala, Lingegowda S., Zand, Behrouz, Stagg, Loren J., Ladbury, John E., Ozpolat, Bulent, Alpay, S. Neslihan, Nishimura, Masato, Stone, Rebecca L., Matsuo, Koji ... Sood, Anil K. (2015). Erythropoietin stimulates tumor growth via EphB4. Cancer Cell, 28 (5), 610-622. doi: 10.1016/j.ccell.2015.09.008

Erythropoietin stimulates tumor growth via EphB4

2015

Journal Article

Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy

Gaur, Sanchaika, Wen, Yunfei, Song, Jian H., Parikh, Nila U., Mangala, Lingegowda S., Blessing, Alicia M., Ivan, Cristina, Wu, Sherry Y., Varkaris, Andreas, Shi, Yan, Lopez-Berestein, Gabriel, Frigo, Daniel E., Sood, Anil K. and Gallick, Gary E. (2015). Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget, 6 (30), 29161-29177. doi: 10.18632/oncotarget.4971

Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy

2015

Journal Article

Nanotechnology: future of oncotherapy

Gharpure, Kshipra M., Wu, Sherry Y., Li, Chun, Lopez-Berestein, Gabriel and Sood, Anil K. (2015). Nanotechnology: future of oncotherapy. Clinical Cancer Research, 21 (14), 3121-3130. doi: 10.1158/1078-0432.CCR-14-1189

Nanotechnology: future of oncotherapy

2015

Journal Article

XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A

Miyake, Takahito, Pradeep, Sunila, Wu, Sherry Y., Rupaimoole, Rajesha, Zand, Behrouz, Wen, Yunfei, Gharpure, Kshipra M., Nagaraja, Archana S., Hu, Wei, Cho, Min Soon, Dalton, Heather J., Previs, Rebecca A., Taylor, Morgan L., Hisamatsu, Takeshi, Kang, Yu, Liu, Tao, Shacham, Sharon, McCauley, Dilara, Hawke, David H., Wiktorowicz, John E., Coleman, Robert L. and Sood, Anil K. (2015). XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A. Clinical Cancer Research, 21 (14), 3286-3297. doi: 10.1158/1078-0432.CCR-14-1953

XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A

Current funding

  • 2025 - 2029
    Improving efficacy and reducing side effects of cancer nanomedicines
    NHMRC IDEAS Grants
    Open grant
  • 2023 - 2026
    In vivo genetic engineering of T-cells for cancer treatment using novel exosome mimetic nanoparticles
    NHMRC IDEAS Grants
    Open grant

Past funding

  • 2019
    Advanced Nanoparticle, Colloid and Microparticle Characterisation and Precision Engineering Nanosystems Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019
    Harnessing the immune system to battle ovarian cancer: A novel approach using naturally occurring exosomes
    UQ Foundation Research Excellence Awards
    Open grant
  • 2019 - 2022
    Harnessing the immune system to battle ovarian cancer: A novel approach using naturally occurring exosomes
    NHMRC Project Grant
    Open grant
  • 2019
    Vevo 3100 Imaging System for ultrahigh resolution and frame rate echocardiographic assessment of small animals.
    UQ Major Equipment and Infrastructure
    Open grant
  • 2018 - 2021
    Re-activating anti-tumour immunity by targeting N-MYC-Lec7 axis in ovarian cancer
    Ovarian Cancer Research Foundation
    Open grant
  • 2018
    Re-activating anti-tumour immunity by targeting N-MYC-Lec7 axis in ovarian cancer
    Ovarian Cancer Research Foundation
    Open grant
  • 2018 - 2020
    Re-activating anti-tumor immunity using non-coding RNAs
    Ovarian Cancer Research Foundation Alliance
    Open grant

Availability

Dr Sherry Wu is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Developing new strategies to overcome immune suppression in cancer

    Principal Advisor

  • Doctor Philosophy

    Development of a new approach to target exosomes for cancer treatment

    Principal Advisor

    Other advisors: Professor Gregory Monteith

  • Doctor Philosophy

    Developing novel strategies to overcome immune suppression in cancer

    Principal Advisor

  • Doctor Philosophy

    Developing clinically translatable nano-systems to break down immune barriers in cancer

    Principal Advisor

    Other advisors: Associate Professor Peter Moyle

Completed supervision

Enquiries

For media enquiries about Dr Sherry Wu's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au